Prithviraj Bose, MD, The University of Texas MD Anderson Cancer, Houston, TX, comments on topical clinical trials investigating the treatment of myeloproliferative neoplasms (MPNs). Specifically discussed is the Phase II study (NCT04254978) of bomedemstat for essential thrombocythemia and the PTG-300-04 study (NCT04057040) on rusfertide for polycythemia vera. Dr Bose also talks on eagerly awaited results on the novel agents selinexor and AVID200. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
Prithviraj Bose, MBBS, has received honoraria from Incyte, Celgene, BMS, CTI BioPharma, Sierra Oncology, Novartis, Blueprint Medicines and Kartos; and has received research support from Incyte, Celgene, BMS, CTI BioPharma, Constellation, Kartos, Blueprint Medicines, Astellas, Pfizer, Promedior and NS Pharma.